Hypoxia-inducible factor prolyl hydroxylase Inhibitors (HIF-PHIs) for treatment of anaemia in chronic kidney disease: guidelines for South Asia

Published by Bhaumik S, Tyagi J, Sharma I et al (for South Asia HIF-PHI Guideline Development Group ) on May 22, 2023

View

Disclaimer

Sponsors

Contact

Abstract

Language

en-gb

PICOS

PICO 10.1

Population
Management of Anaemia in Non-Dialysis dependent Chronic Kidney Disease with Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors- A Systematic Review
Intervention
Desidustat any dose
Comparator
Darbepoetin Alpha
Outcomes

PICO 10.1

Population
Management of Anaemia in Dialysis-dependent Chronic Kidney Disease with Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors
Intervention
Desidustat
Comparator
Epoetin alpha
Outcomes

PICO 10.2

Population
Management of Anaemia in Non-Dialysis dependent Chronic Kidney Disease with Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors- A Systematic Review
Intervention
Desidustat 100 mg
Comparator
Placebo
Outcomes

PICO 10.3

Population
Management of Anaemia in Non-Dialysis dependent Chronic Kidney Disease with Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors- A Systematic Review
Intervention
Desidustat 150 mg
Comparator
Placebo
Outcomes

PICO 10.4

Population
Management of Anaemia in Non-Dialysis dependent Chronic Kidney Disease with Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors- A Systematic Review
Intervention
Desidustat 200 mg
Comparator
Placebo
Outcomes

PICO 20.1

Population
Management of Anaemia in Non-Dialysis dependent Chronic Kidney Disease with Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors- A Systematic Review
Intervention
Daprodustat any dose
Comparator
Placebo
Outcomes

PICO 20.1

Population
Management of Anaemia in Dialysis-dependent Chronic Kidney Disease with Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors
Intervention
Daprodustat
Comparator
ESA [rhEPO/Darbepoetin Alpha/Epoetin Alpha]
Outcomes

PICO 20.2

Population
Management of Anaemia in Non-Dialysis dependent Chronic Kidney Disease with Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors- A Systematic Review
Intervention
Daprodustat any dose
Comparator
rhEPO (Epoetins or their biosimilars or Darbepoetin)
Outcomes

PICO 20.2

Population
Management of Anaemia in Dialysis-dependent Chronic Kidney Disease with Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors
Intervention
Daprodustat
Comparator
Placebo
Outcomes

PICO 20.3

Population
Management of Anaemia in Dialysis-dependent Chronic Kidney Disease with Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors
Intervention
Daprodustat 10 mg
Comparator
Placebo
Outcomes

PICO 20.4

Population
Management of Anaemia in Dialysis-dependent Chronic Kidney Disease with Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors
Intervention
Daprodustat 15 mg
Comparator
Placebo
Outcomes

PICO 20.5

Population
Management of Anaemia in Dialysis-dependent Chronic Kidney Disease with Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors
Intervention
Daprodustat 25 mg
Comparator
Placebo
Outcomes

PICO 20.6

Population
Management of Anaemia in Dialysis-dependent Chronic Kidney Disease with Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors
Intervention
Daprodustat 30 mg
Comparator
Placebo
Outcomes

PICO 20.7

Population
Management of Anaemia in Dialysis-dependent Chronic Kidney Disease with Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors
Intervention
Daprodustat
Comparator
Placebo for 4 weeks followed by ESA upto 24 weeks
Outcomes

PICO 30.1

Population
Management of Anaemia in Dialysis-dependent Chronic Kidney Disease with Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors
Intervention
Enarodustat any dose
Comparator
Darbepoetin alpha
Outcomes

PICO 30.1

Population
Management of Anaemia in Non-Dialysis dependent Chronic Kidney Disease with Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors- A Systematic Review
Intervention
Enarodustat any dose
Comparator
Darbepoetin alpha
Outcomes

PICO 30.2

Population
Management of Anaemia in Dialysis-dependent Chronic Kidney Disease with Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors
Intervention
Enarodustat any dose
Comparator
Placebo
Outcomes

PICO 30.2

Population
Management of Anaemia in Non-Dialysis dependent Chronic Kidney Disease with Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors- A Systematic Review
Intervention
Enarodustat any dose
Comparator
Placebo
Outcomes

PICO 30.3

Population
Management of Anaemia in Dialysis-dependent Chronic Kidney Disease with Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors
Intervention
Enarodustat 2 mg
Comparator
Placebo
Outcomes

PICO 30.4

Population
Management of Anaemia in Dialysis-dependent Chronic Kidney Disease with Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors
Intervention
Enarodustat 4 mg
Comparator
Placebo
Outcomes

PICO 30.5

Population
Management of Anaemia in Dialysis-dependent Chronic Kidney Disease with Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors
Intervention
Enarodustat 6 mg
Comparator
Placebo
Outcomes

PICO 40.1

Population
Management of Anaemia in Non-Dialysis dependent Chronic Kidney Disease with Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors- A Systematic Review
Intervention
Molidustat any dose
Comparator
Placebo
Outcomes

PICO 40.1

Population
Management of Anaemia in Dialysis-dependent Chronic Kidney Disease with Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors
Intervention
Molidustat
Comparator
ESA [Epoetin alpha/Epoetin beta/ Darbepoetin alpha]
Outcomes

PICO 40.2

Population
Management of Anaemia in Non-Dialysis dependent Chronic Kidney Disease with Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors- A Systematic Review
Intervention
Molidustat any dose
Comparator
Darbepoetin alpha
Outcomes

PICO 50.1

Population
Management of Anaemia in Dialysis-dependent Chronic Kidney Disease with Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors
Intervention
Roxadustat
Comparator
ESA [Epoetin alpha/Darbepoetin alpha]
Outcomes

PICO 50.1

Population
Management of Anaemia in Non-Dialysis dependent Chronic Kidney Disease with Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors- A Systematic Review
Intervention
Roxadustat any dose
Comparator
Placebo
Outcomes

PICO 50.2

Population
Management of Anaemia in Non-Dialysis dependent Chronic Kidney Disease with Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors- A Systematic Review
Intervention
Roxadustat any dose
Comparator
Darbepoetin alpha
Outcomes

PICO 60.1

Population
Management of Anaemia in Non-Dialysis dependent Chronic Kidney Disease with Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors- A Systematic Review
Intervention
Vadadustat any dose
Comparator
Darbepoetin alpha
Outcomes

PICO 60.1

Population
Management of Anaemia in Dialysis-dependent Chronic Kidney Disease with Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors
Intervention
Vadadustat any dose
Comparator
Placebo
Outcomes

PICO 60.2

Population
Management of Anaemia in Non-Dialysis dependent Chronic Kidney Disease with Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors- A Systematic Review
Intervention
Vadadustat any dose
Comparator
Placebo
Outcomes

PICO 60.2

Population
Management of Anaemia in Dialysis-dependent Chronic Kidney Disease with Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors
Intervention
Vadadustat 150 mg
Comparator
Placebo
Outcomes

PICO 60.3

Population
Management of Anaemia in Dialysis-dependent Chronic Kidney Disease with Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors
Intervention
Vadadustat 300 mg
Comparator
Placebo
Outcomes

PICO 60.4

Population
Management of Anaemia in Dialysis-dependent Chronic Kidney Disease with Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors
Intervention
Vadadustat 600 mg
Comparator
Placebo
Outcomes

PICO 60.5

Population
Management of Anaemia in Dialysis-dependent Chronic Kidney Disease with Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors
Intervention
Vadadustat
Comparator
Darbepoetin alpha
Outcomes